Testing for Respiratory Viruses in Suspected Viral Myocarditis
Yes, obtain a respiratory viral panel including SARS-CoV-2 and influenza testing in this patient with suspected viral myocarditis, as identifying the specific viral etiology can directly inform treatment decisions and prognosis. 1
Rationale for Viral Testing
The clinical presentation—one month of viral prodrome followed by chest pain, diffuse ST elevations, and non-obstructive coronaries—strongly suggests viral myocarditis (meeting criteria for at least "possible myocarditis" per ACC definitions). 1 The underlying viral cause matters because:
COVID-19 myocarditis has specific treatment implications: Patients with confirmed COVID-19 myocarditis and ongoing need for supplemental oxygen should receive corticosteroids. 1 Intravenous corticosteroids may be considered in those with hemodynamic compromise or multisystem inflammatory syndrome in adults (MIS-A). 1
Viral identification affects surveillance and follow-up: COVID-19 is associated with post-acute sequelae (PASC-CVD) that can manifest ≥4 weeks after infection, including myocarditis, pericarditis, and persistent cardiovascular symptoms. 1 This patient's one-month prodrome followed by acute cardiac presentation fits this pattern.
Co-infections occur and influence severity: While rare (0.7% overall), SARS-CoV-2 and influenza co-infection occurs more frequently in critically ill patients (2.2%) and can worsen outcomes. 2 Testing for both simultaneously is efficient and clinically relevant.
Practical Testing Approach
Order a multiplex respiratory viral panel that includes SARS-CoV-2, influenza A/B, and RSV from a nasopharyngeal swab. 3, 4 Modern multiplex PCR assays can detect multiple respiratory viruses simultaneously with high sensitivity (>96% positive agreement) and provide results within 1 hour. 4
The American Thoracic Society endorses nucleic acid amplification tests (NAATs) over rapid antigen tests for respiratory viral diagnosis in patients with respiratory illness. 3 While their guideline specifically addresses community-acquired pneumonia, the principle applies here given the viral prodrome and suspected viral myocarditis.
Clinical Caveats
Timing matters: The one-month interval between viral symptoms and cardiac presentation is consistent with post-acute COVID-19 cardiovascular sequelae but may reduce the likelihood of detecting active viral shedding. 1 However, testing remains valuable for epidemiologic tracking and guiding empiric therapy decisions.
Negative testing doesn't exclude viral myocarditis: If the respiratory panel is negative, this patient still has suspected viral myocarditis based on clinical criteria and should be managed accordingly with cardiac MRI to confirm diagnosis and assess severity. 1
Treatment shouldn't wait for results: Given the clinical presentation, initiate supportive care immediately. If the patient has concurrent pneumonia requiring oxygen, start corticosteroids empirically while awaiting viral testing results. 1
Additional Diagnostic Workup
Beyond viral testing, this patient requires:
- Cardiac MRI to confirm myocarditis diagnosis and assess for late gadolinium enhancement, T1/T2 prolongation, and extent of myocardial involvement 1
- Inflammatory markers including C-reactive protein and ferritin (elevated in MIS-A) 1
- Serial troponin and ECG monitoring 1
- Echocardiogram to assess ventricular function and wall motion abnormalities 1
The combination of viral testing with advanced cardiac imaging provides the most complete diagnostic picture and guides both acute management and long-term follow-up strategies. 1